Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration
SAN FRANCISCO and SUZHOU, China, Jan. 3, 2025 /PRNewswire/ — Innovent Biologics,…